Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.52 |
| ▸ | CTSK | P43235 | 5/20 | 0.52 |
| ▸ | CTSB | P07858 | 4/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31106950 | 1.00 | CTSS (0.52) | CTSSCTSKCTSBBCL2ACE | |
| SCHEMBL10156301 | 0.89 | KLK5 (0.55) | CTSSCTSKCTSBBCL2ACE | |
| SCHEMBL29722671 | 0.88 | ACE (0.60) | CTSSCTSKCTSBBCL2ACE | |
| SCHEMBL28789425 | 0.88 | ACE (0.60) | CTSSCTSKCTSBBCL2ACE | |
| SCHEMBL4546557 | 0.88 | ACE (0.60) | CTSSCTSKCTSBBCL2ACE | |
| SCHEMBL14999574 | 0.86 | POLB (0.47) | ACETACR1POLBMAPT | |
| SCHEMBL1827307 | 0.86 | P2RX7 (0.53) | CTSSCTSKCTSBBCL2ACE | |
| SCHEMBL20905929 | 0.86 | CTSS (0.56) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL14576685 | 0.86 | CTSS (0.56) | CTSSCTSKCTSBACECTSL | |
| SCHEMBL30051055 | 0.86 | CTSS (0.56) | CTSSCTSKCTSBACECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| US-20220073500-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| US-11028077-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-06-08 | — | — | US | disclosed |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9890141-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890141-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9708303-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | SARCODE BIOSCIENCE INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20130150585-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARcode Bioscience, Inc. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8367701-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367701-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE BIOSCIENCE INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8080562-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080562-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028077-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | VCAM1, ICAM1, HLA-DRB1 | CTSS 658/4885CTSK 978/4885CTSB 420/4885 |
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | CTSS 658/4885CTSK 978/4885CTSB 420/4885 |
| US-20220073500-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | CTSS 658/4885CTSK 978/4885CTSB 420/4885 |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | VCAM1, ICAM1, HLA-DRB1 | CTSS 658/4885CTSK 978/4885CTSB 420/4885 |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | CTSS 658/4885CTSK 978/4885CTSB 420/4885 |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | CTSS 658/4885CTSK 978/4885CTSB 420/4885 |
| US-20130150585-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | CTSS 658/4885CTSK 978/4885CTSB 420/4885 |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | ITGB1, ITGA1, VCAM1 | CTSS 2119/4885CTSK 1932/4885CTSB 1530/4885 |
| US-20180118726-A1 | LFA-1 INHIBITOR AND METHODS OF PREPARATION AND POLYMORPH THEREOF | ITGB1, ITGA1, VCAM1 | CTSS 2119/4885CTSK 1932/4885CTSB 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.